إسرائيل - العربية - Ministry of Health

teva pharmaceutical indust.ltd - montelukast as sodium 10 mg - tablets - montelukast - montelukast teva is indicated in adult and adolescents 15 years of age and older for the prophylaxis and chronic treatment of asthma including prevention of daytime and nighttime symptoms the treatment of aspirin-sensitive asthmatic patients and the prevention of exercise-induced bronchoconstriction. montelukast teva is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma. montelukast teva and inhaled corticosteroids may be used concomitantly with additive effects to control asthma or to reduce the inhaled corticosteroid dose while maintaining clinical stability. montelukast teva is indicated for the relief of symptoms of seasonal allergic rhinitis in adults and adolescents 15 years of age and older.

إسرائيل - العربية - Ministry of Health

salomon,levin & elstein ltd - loteprednol etabonate 5 mg / 1 ml - ophthalmic suspension - loteprednol - lotemax is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to otain an advisable diminution in edema and inflammation. lotemax is less effective than prednisolone acetate 1 % in two 28 day controlled clinical studies in acute anterior uveitis, where 72 % of patients treated with lotemax experienced resolution of anterior chamber cells, compared to 87 % of patients treated with prednisolone acetate 1 % . the incidence of patients with clinically significant increases in iop (> or = 10 mmhg) was 1 % with lotemax adn 6 % with prednisolone acetate 1 %. lotemax should not be used in patients who require a more potent corticosteroid for this indication. lotemax is also indicated for the treatment of po

إسرائيل - العربية - Ministry of Health

teva pharmaceutical indust.ltd - dorzolamide as hydrochloride 2 % - ophthalmic solution - dorzolamide - for the treatment of elevated intracular pressure (iop) in patients with ocular hypertension, open-angle glaucoma and in some patients with secondary glaucoma.

إسرائيل - العربية - Ministry of Health

abic marketing ltd - dorzolamide as hydrochloride 2 %; timolol as maleate 0.5 % - ophthalmic solution - timolol - for the treatment of elevated intracular pressure (iop) in patients with ocular hypertension, open-angle glaucoma, or other secondary open-angle glaucoma, when concomitant therapy is appropriate.

إسرائيل - العربية - Ministry of Health

teva pharmaceutical indust.ltd - dexamethasone as sodium phosphate 1 mg/ml; neomycin as sulfate 5 mg/ml - ophthalmic solution - neomycin - steroid-responsive allergic and inflammatory disorders of the anterior segments of the eye (conjunctival, corneal, or uveal tract inflammation) or mechanical, chemical or thermal trauma where bacterial infection or a risk of bacterial ocular infection exists.

إسرائيل - العربية - Ministry of Health

teva pharmaceutical indust.ltd - ciprofloxacin as hydrochloride 250 mg - tablets - ciprofloxacin - broad spectrum antibiotic for infections caused by ciprofloxacin sensitive pathogens: invasive infections of the external ear. treatment of acute pulmonary exacerbation of cystic fibrosis associated with p. aeruginosa infections in pediatric patients aged 5-17 years.

إسرائيل - العربية - Ministry of Health

sanofi - aventis israel ltd - ramipril 2.5 mg - tablets - ace inhibitors, plain - hypertension congestive heart failure reduction of mortality in patients after mi with left ventricular dysfunction. for reducing the risk of myocardial infarction stoke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1g/day.